CERRITOS, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that it will join the Russell 2000® and Russell 3000® after the 2025 Russell indexes annual reconstitution, effective after the US market closes on June 27, according to a preliminary list of additions posted on May 23. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 30, ranking them ...

The Oncology Institute (TOI) Q1 2025 Earnings Call May 14, 2025 05:00 PM ET Company Participants Mark Hueppelsheuser - General CounselDaniel Virnich - Chief Executive OfficerRob Carter - Chief Financial OfficerDavid Larsen - Managing DirectorYuan Zhi - Managing DirectorBill Sutherland - Director of Research Conference Call Participants Robert Leboyer - Senior Biotechnology Analyst Operator Good afternoon, and welcome to the Oncology Institute's First Quarter twenty twenty five Earnings Conference Call. Toda ...

The Oncology Institute (TOI) Q1 2025 Earnings Call May 14, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to the Oncology Institute's First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded, and we have allocated one hour for prepared remarks and Q and A. At this time, I'd like to turn the conference over to Mark Heplheiser, General Counsel at TOI. Thank you. You may begin. Speaker1 The press release announcing the Oncology Institute's results for the first quarter o ...

Exhibit 99.1 The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance CERRITOS, Calif., May 14, 2025 -- The Oncology Institute, Inc. (NASDAQ: TOI) ("TOI" or the "Company"), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights First Quarter 2025 Financial Highlights • Retail Pharmacy and Dispensary set fill records, contributing $ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number 001-39248 The Oncology Institute, Inc. (Exact name of registrant as specified in its charter) Delaware 84-3562323 (State ...

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of the largest value-based community oncology groups in the United States, today reported financial results for its three months ended March 31, 2025. Recent Operational Highlights Retail Pharmacy and Dispensary set fill records, contributing $49.3 million revenue and over $9 million in gross profit in Q1. The Pharmacy and Dispensary segment grew over 20% in the first quarter of 2025 v ...

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that Dr. Jeffrey Langsam will assume the role of enterprise Chief Clinical Officer effective May 13th, 2025. The CCO role will oversee therapeutics including pathway and procurement decisions, utilization management, and MSO practice clinical engagement. Dr. Langsam joins TOI from Cigna Healthcare, where he was the Nationa ...

Company Overview - Topicus.com Inc. is a leading pan-European provider of vertical market software and platforms, serving clients in both public and private sectors [3] - The company focuses on acquiring, building, and managing software companies that deliver specialized, mission-critical, and high-impact software solutions tailored to customer needs [3] Board of Directors - At the annual general meeting held on May 13, 2025, all five director nominees were elected to the board: John Billowits, Alex Macdonald, Lori O'Neill, Donna Parr, and Robin van Poelje [1] - Jane Holden did not stand for re-election, and the company expressed gratitude for her contributions as a board member [2]

CERRITOS, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, today announced that Dr. Daniel Virnich, Chief Executive Officer, and Rob Carter, Chief Financial Officer, will participate in B. Riley’s 25th Annual Institutional Investor Conference in Marina Del Rey, CA on May 21st, 2025. About The Oncology Institute Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-bas ...

CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patient ...